News
globenewswire.comBBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progressglobenewswire.comMay 12
globenewswire.comBridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.comMay 12
247wallst.comHere Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More247wallst.comMay 11
globenewswire.comBBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026globenewswire.comApr 22
globenewswire.comBBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairmanglobenewswire.comApr 22